サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1512648

口唇ヘルペス治療薬の世界市場：2024年～2031年

Global Herpes Labialis Drugs Market - 2024-2031

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.05円
口唇ヘルペス治療薬の世界市場：2024年～2031年
出版日: 2024年07月10日
発行: DataM Intelligence
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の口唇ヘルペス治療薬市場は、2023年に11億6,000万米ドルに達し、2024-2031年の予測期間中にCAGR 4.8％で成長し、2031年には17億米ドルに達すると予測されています。

口唇ヘルペスはコールドソアとも呼ばれ、通常、口の近くや顔の他の部位に現れます。口唇ヘルペスは単純ヘルペスウイルス1型（HSV-1）によって引き起こされるが、時には単純ヘルペスウイルス2型（HSV-2）によって引き起こされることもあります。口唇ヘルペスウイルスは通常、個人間の非性的接触によって感染し、日光への曝露、発熱、ストレス、月経周期によって発症が誘発されます。

世界の口唇ヘルペス治療薬市場は、再発を繰り返す口唇ヘルペスに対する単発的治療の採用により、近年大きく成長しています。例えば、免疫不全患者では、アシクロビル200～400mgを1日5回5日間、バラシクロビル2000mgを12時間ごとに1日間、ファムシクロビル1500mgを単回投与するほか、経口抗ウイルス薬、外用クリーム・軟膏、免疫調節薬などを使用します。

市場力学：

促進要因

口唇ヘルペス治療薬の製品上市とFDA承認の増加

世界の口唇ヘルペス治療薬市場の需要は、複数の要因によって牽引されています。主な要因の1つは、口唇ヘルペス治療薬の製品上市の増加とFDA承認の増加です。

単純ヘルペスウイルスは主に皮膚と皮膚の接触によって広がり、治療可能だが完治はしないです。口唇ヘルペスは通常、口唇、歯茎、喉に小さくて痛みを伴う水疱を発症させる口腔領域に影響を及ぼします。

さらに、市場の主要企業は口唇ヘルペスの治療に注力しており、革新的な製品の発売と承認がこの市場の成長を促進すると思われます。このような効果的な製品の発売は、研究の発見を新たな治療法に変え、数百万人の口唇ヘルペス患者の治療を改善するのに役立ちます。

例えば、2023年5月、Outbreaks Inc.は、冷え症と熱性水疱の革新的な外用療法であるAZZURXの発売を発表しました。この治療薬は、希少な天然エッセンシャルオイルの独自ブレンドに懸濁された4種類の植物性ホメオパシー有効成分で構成されています。AZZURXは、発生を未然に防ぎ、発生を短期化し、不快感を軽減しながら治癒を促進するよう処方されています。

また、ザイダスライフサイエンス社は2023年3月、顔や唇の冷え症の治療に使用されるアシクロビルクリーム5％の最終承認を米国食品医薬品局（FDA）から取得したと発表しました。アシクロビルは、抗ウイルス薬として知られる医薬品の一群に属します。

阻害要因

抗ウイルス薬耐性、薬物治療に伴う副作用、効果的なワクチンの限られた入手可能性、高額な治療費、個人の認識不足などの要因が、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 口唇ヘルペス治療薬の上市とFDA承認の増加
      • 口唇ヘルペスの有病率の上昇
    • 抑制要因
      • 抗ウイルス薬の耐性
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析
  • DMI見解

第6章 菌株タイプ別

  • 単純ヘルペスウイルス1型
  • 単純ヘルペスウイルス2型

第7章 薬剤タイプ別

  • アシクロビル
  • バラシクロビル
  • ペンシクロビル
  • ファムシクロビル
  • ドコサノール
  • その他

第8章 投与経路別

  • 外用
  • 経口
  • 注射

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第12章 企業プロファイル

  • GlaxoSmithKline Pharmaceuticals
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Bauch Health Inc.
  • Novartis AG
  • Zhejiang Charioteer Pharmaceutical Co. Ltd
  • Teva Pharmaceuticals
  • TCI Chemicals
  • Olon Group
  • ChemWerth Inc
  • Viatris Inc
  • Tecoland Corporation

第13章 付録

目次
Product Code: PH8506

Overview

The global herpes labialis drugs market reached US$ 1.16 billion in 2023 and is expected to reach US$ 1.7 billion by 2031 growing with a CAGR of 4.8% during the forecast period 2024-2031.

Herpes labialis, also termed as cold sores usually appears near the mouth or on other areas of the face. Cold sores are caused by herpes simplex virus type 1 (HSV-1) but occasionally by herpes simplex virus type 2 (HSV-2). The herpes labialis virus is usually transmitted through non-sexual contact between individuals, and outbreaks can be triggered by exposure to sunlight, fever, stress, or menstrual cycles.

The global herpes labialis drug market has grown significantly in recent years due to adopting episodic treatment for recurrent herpes labialis. For instance, in immunocompetent patients, Acyclovir 200-400 mg is taken 5 times a day for 5 days, Valacyclovir 2000 mg every 12 hours for 1 day, and Famciclovir 1500 mg as a single dose, and also oral antiviral medication, topical creams & ointment, and immunomodulators.

Market Dynamics: Drivers

Increasing product launches and rising fda approvals of drugs for herpes labialis drugs

The demand for the global herpes labialis drugs market is driven by multiple factors. One of the primary factors is the increasing product launches and rising FDA approvals of drugs for herpes labialis treatment.

Herpes simplex virus primarily spreads by skin-to-skin contact and is treatable but not curable. Herpes labilalis usually affects the mouth area which causes small, painful blisters to develop on the lips, gums, or throat.

Moreover, key players in the market focus on the treatment of herpes labialis, and innovative product launches and approvals would propel this market growth. These effective product launches help to transform research discoveries into new treatments and improve care for millions of people with herpes labialis.

For instance, in May 2023, Outbreaks Inc. announced the launch of AZZURX, an innovative topical therapy for cold sores and fever blisters. This therapy comprises four active botanical homeopathic ingredients suspended in a proprietary blend of rare natural essential oils. AZZURX is formulated to stop outbreaks before they erupt, shorten active outbreaks, and promote healing while reducing discomfort.

Also, in March 2023, Zydus Lifesciences Ltd. announced that it has received final approval from the United States Food and Drug Administration (U.S FDA) for Acyclovir Cream 5% which is used to treat cold sores on the face and lips. Acyclovir belongs to a class of medicines known as antivirals.

Restraints

Factors such as antiviral drug resistance, side effects associated with the treatment of drugs, limited availability of effective vaccines, high cost of the treatment, and lack of awareness among individuals are expected to hamper the market.

Segment Analysis

The global herpes labialis drugs market is segmented based on strain type, drug type, route of administration, distribution channel, and region.

The acyclovir segment accounted for approximately 56.5% of the global herpes labialis drugs market share

The acyclovir segment is expected to hold the largest market share over the forecast period. Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes.

Moreover, key players in the industry launching new drugs and approvals for acyclovir are expected to boost the segment's market growth. For instance, in May 2023, Modavar Pharmaceuticals announced that it had launched Acyclovir Capsules. The launch of the 200mg strength of Acyclovir adds to the growing line of products in the Modavar portfolio. The product is available immediately and is AB-rated to Mylan's Zovirax. It is indicated for the treatment of Cold Sores (caused by Herpes Simplex, HSV-1), Shingles (caused by Herpes Zoster), Genital Herpes (HSV-2), and Chickenpox.

Also, in October 2022, Camber Pharmaceuticals introduced Acyclovir Oral Suspension and extended its current portfolio. Acyclovir Oral Suspension is an artificial nucleoside analog functional in herpes virus treatment.

In addition, the rising number of clinical trials in the treatment of herpes labialis would drive this segment's growth. According to clinicalTrials.gov, in July 2023, Bayer conducted a clinical trial on the study to compare sitavig (acyclovir) buccal tablet with a placebo in the treatment of herpes labialis in immunocompetent adults.

Geographical Analysis

North America accounted for approximately 43.2% of the global herpes labialis drugs market share

North America region is expected to hold the largest market share over the forecast period. The rising prevalence and incidence of herpes simplex virus infection across the globe act as a primary driver for the herpes labialis drug market. According to WHO data in August 2023, an estimated 3.7 billion people under age 50 (67%) globally have herpes simplex virus type 1 (HSV-1) infection which is the main cause of oral herpes. Also, an estimated 491 million people aged 15-49 (13%) worldwide have herpes simplex virus type 2 (HSV-2) infection which is the main cause of genital herpes.

Moreover, in this region, major key players are presence, increasing FDA approvals for HSV-1 gene therapy, technological advancements, and rising research and developments in herpes labialis treatment.

For instance, in May 2023, the U.S. Food and Drug Administration approved Vyjuvek which is a herpes simplex virus type 1 (HSV-1) vector-based gene therapy. Vyjuvek is a genetically modified herpes-simplex virus used to deliver normal copies of the COL7A1 gene to wounds. Vyjuvek is mixed into an excipient gel before topical application.

Market Segmentation

By Stain Type

  • Herpes Simplex Virus Type-1
  • Herpes Simplex Virus Type-2

By Drug Type

  • Acyclovir
  • Valacyclovir
  • Penciclovir
  • Famciclovir
  • Docosanol
  • Others

Route of Administration

  • Topical
  • Oral
  • Injectables

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the herpes labialis drugs market include GlaxoSmithKline Pharmaceuticals, Bauch Health Inc., Novartis AG, Zhejiang Charioteer Pharmaceutical Co. Ltd, Teva Pharmaceuticals, TCI Chemicals, Olon Group, ChemWerth Inc., Viatris Inc., and Tecoland Corporation among others.

Key Developments

  • In July 2023, Replimune Group, Inc. and Incyte announced a collaboration and supply agreement to study RP1, Replimune's lead product in combination with INCB99280, Incyte's small molecule oral PD-L1 inhibitor. RP1 is Replimune's lead oncolytic immunotherapy product candidate and is based on a proprietary new strain of herpes simplex virus engineered for tumor-selective replication.
  • In May 2023, Mylab Discovery Solutions launched PathoDetect for HSV Type 1& 2 Detection kit which is a multiplex real-time PCR test to detect and differentiate herpes simplex virus type I (HSV-l) and type 2 (HSV-2) in a single tube. It is approved by CDSCO and delivers high sensitivity and specificity in the detection of HSV-1 and HSV-2 DNA in clinical specimens.
  • In January 2023, Molbio Diagnostics announced that it had launched the Truenat HSV 1/2 for testing the Herpes Simplex Virus. The test is approved by CDSCO and can provide sample-to-test results. This real-time PCR test works on the existing Truelab infrastructure and does not require any additional setup and equipment to run the test.
  • In December 2022, BioNTech announced that the first subject was dosed in a first-in-human Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1.
  • In August 2022, Rational Vaccines announced a clinical trial to determine baseline characteristics of patients diagnosed with recurrent symptomatic herpes simplex type 2 (HSV-2) virus.

Why Purchase the Report?

  • To visualize the global herpes labialis drug market segmentation based on the strain type, drug type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the global herpes labialis drugs market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global herpes labialis drugs market report would provide approximately 70 tables, 64 figures, and 182 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Strain Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Launches and Rising FDA Approvals of Drugs for Herpes labialis drugs
      • 4.1.1.2. Rising Prevalence of Herpes Labialis
    • 4.1.2. Restraints
      • 4.1.2.1. Antiviral Drugs Resistance
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. By Strain Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain Type
    • 6.1.2. Market Attractiveness Index, By Strain Type
  • 6.2. Herpes Simplex Virus Type-1 *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Herpes Simplex Virus Type-2

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Acyclovir
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Valacyclovir
  • 7.4. Penciclovir
  • 7.5. Famciclovir
  • 7.6. Docosanol
  • 7.7. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Topical*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oral
  • 8.4. Injectables

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Strain Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Strain Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Strain Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Strain Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Strain Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Product Benchmarking
  • 11.3. Company Share Analysis
  • 11.4. Key Developments and Strategies

12. Company Profiles

  • 12.1. GlaxoSmithKline Pharmaceuticals*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bauch Health Inc.
  • 12.3. Novartis AG
  • 12.4. Zhejiang Charioteer Pharmaceutical Co. Ltd
  • 12.5. Teva Pharmaceuticals
  • 12.6. TCI Chemicals
  • 12.7. Olon Group
  • 12.8. ChemWerth Inc
  • 12.9. Viatris Inc
  • 12.10. Tecoland Corporation

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us